Variable | Odds ratio | 95% confidence interval | P value |
---|---|---|---|
PDC (≥ 80% vs. <50%) | 0.81 | (0.515, 1.231) | 0.48 |
PDC (≥ 50% ≤80% vs. < 50%) | 0.91 | (0.479, 1.741) | 0.94 |
Age | 1.00 | (0.976, 1.016) | 0.66 |
Gender (Female vs. Male) | 1.37 | (0.796, 2.368) | 0.25 |
Race (Black vs. White) | 1.41 | (0.558, 3.538) | 0.48 |
Race (Hispanic vs. White) | 0.42 | (0.048, 3.599) | 0.29 |
Race (Other vs. White) | 1.80 | (0.689, 4.703) | 0.22 |
Fracture in 6 Month Period before Initiating Teriparatide | 2.93 | (2.084, 4.122) | <.0001 |
Charlson Comorbidity | 0.96 | (0.861, 1.07) | 0.46 |
Geographic Region (West vs. Northeast) | 1.38 | (0.347, 5.513) | 0.99 |
Geographic Region (Southeast vs. Northeast) | 2.07 | (0.566, 7.531) | 0.05 |
Geographic Region (Midwest vs. Northeast) | 1.29 | (0.341, 4.889) | 0.76 |
Bisphosphonate Use | 1.04 | (0.738, 1.469) | 0.82 |
Calcitonin Use | 0.62 | (0.283, 1.378) | 0.24 |
Selective Estrogen Receptor Modulator Use | 1.16 | (0.551, 2.433) | 0.70 |
Estrogen Use | 0.61 | (0.197, 1.891) | 0.39 |